Opsens files patent application for OptoWire diagnostic tool for measuring FFR

Opsens Inc. announces that it has recently filed a patent application for the OptoWire, a second diagnostic tool to assess coronary lesions by doing Fractional Flow Reserve ("FFR").

Opsens' in-house team has been developing the OptoWire in parallel with the EasyWire, unveiled at the end of December 2010, also for use in FFR.

OptoWire for the measurement of FFR

Unlike traditional guide wires, the OptoWire is a guide wire instrumented with a fiber optic pressure sensor, which is drift free and provides a high fidelity measurement of blood pressure in coronary arteries. In addition to more reliable measurement, the OptoWire offers better mechanical performance in terms of trackability, torquability and support over other existing pressure guide wires.

"Opsens is developing a complete tool box for cardiologists to use in the measurement of FFR, allowing them to select the right tool for each individual patient," said Claude Belleville, VP Medical. "OptoWire and EasyWire are complementary products: a cardiologist may choose the OptoWire for a diffused lesion or easy-to-reach lesions, while the EasyWire may be better suited for lesions that are more difficult to reach."

FFR supported by strong clinical data

Fractional Flow Reserve is an index of the functional severity of a coronary stenosis that is calculated from pressure measurements taken before and after a narrowing of the arteries during coronary arteriography. This new approach enables an "on the spot" diagnosis for a better assessment as to whether a stent is an appropriate intervention to improve blood circulation in the cardiovascular system.

FFR measurement is an increasingly popular method used in the treatment of cardiac lesions. The FAME Study, published in 2009, outlined the positive outcome this step has on patients' recovery and overall outcome, reducing death rates by over 30%.

Source:

OPSENS INC.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Metagenomic sequencing improves detection of rare pathogens in CNS infections